IRIS UniCatt

De Sanctis, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.275
EU - Europa 3.561
AS - Asia 2.806
SA - Sud America 532
Continente sconosciuto - Info sul continente non disponibili 121
AF - Africa 81
OC - Oceania 7
Totale 11.383
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.091
SG - Singapore 1.333
DE - Germania 817
IT - Italia 759
NL - Olanda 739
CN - Cina 546
BR - Brasile 427
SE - Svezia 341
VN - Vietnam 257
FR - Francia 216
GB - Regno Unito 139
IE - Irlanda 139
IN - India 103
CA - Canada 99
JP - Giappone 89
HK - Hong Kong 85
FI - Finlandia 73
BD - Bangladesh 69
ID - Indonesia 69
RU - Federazione Russa 68
TR - Turchia 47
PL - Polonia 45
ES - Italia 39
MX - Messico 39
KR - Corea 38
AR - Argentina 36
UA - Ucraina 32
IQ - Iraq 26
CO - Colombia 24
ZA - Sudafrica 24
AT - Austria 23
PK - Pakistan 23
EC - Ecuador 18
CZ - Repubblica Ceca 17
BE - Belgio 14
CH - Svizzera 14
IR - Iran 14
EG - Egitto 13
MK - Macedonia 13
SA - Arabia Saudita 13
AE - Emirati Arabi Uniti 12
CI - Costa d'Avorio 11
IL - Israele 11
LT - Lituania 11
RS - Serbia 11
PH - Filippine 10
VE - Venezuela 9
CR - Costa Rica 8
JO - Giordania 8
PA - Panama 8
RO - Romania 8
UZ - Uzbekistan 8
JM - Giamaica 7
MA - Marocco 6
PT - Portogallo 6
PY - Paraguay 6
TH - Thailandia 6
TN - Tunisia 6
MY - Malesia 5
NP - Nepal 5
SK - Slovacchia (Repubblica Slovacca) 5
AU - Australia 4
BG - Bulgaria 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
GR - Grecia 4
OM - Oman 4
PE - Perù 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AL - Albania 3
BY - Bielorussia 3
CL - Cile 3
DZ - Algeria 3
HR - Croazia 3
KE - Kenya 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
QA - Qatar 3
SN - Senegal 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AO - Angola 2
BT - Bhutan 2
DM - Dominica 2
GT - Guatemala 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
ME - Montenegro 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
Totale 11.240
Salva come PNG Salva come JPEG
Città #
Singapore 782
Amsterdam 693
Ashburn 558
San Jose 467
Chandler 333
Los Angeles 193
New York 168
Frankfurt am Main 157
Rome 137
Beijing 116
Dublin 111
Hefei 105
Milan 100
Council Bluffs 90
Tokyo 84
Dallas 83
Ho Chi Minh City 78
Hong Kong 77
Hanoi 69
Jakarta 64
Lauterbourg 64
Tukwila 64
Munich 56
São Paulo 45
Boston 43
Santa Clara 41
Atlanta 38
Helsinki 38
San Mateo 38
Seoul 36
The Dalles 35
Houston 34
Marseille 33
Moscow 32
Chicago 31
Toronto 30
Warsaw 30
Boardman 28
Buffalo 28
Denver 28
Phoenix 28
Princeton 28
Kent 27
Orem 27
Palermo 27
Montreal 25
Nuremberg 25
Brooklyn 24
Poplar 23
Stockholm 22
Da Nang 20
Dearborn 20
London 20
Paris 20
Ann Arbor 19
Düsseldorf 19
San Francisco 19
Wilmington 19
Chennai 18
Mexico City 18
Bremen 17
Turku 16
Jacksonville 15
Johannesburg 15
Nanjing 15
Cattolica 14
Nürnberg 14
Pune 14
Augusta 13
Belo Horizonte 13
Brno 13
Falkenstein 13
Seattle 13
Vienna 13
Ankara 12
Brussels 12
Rio de Janeiro 12
Shanghai 12
Washington 12
Abidjan 11
Bologna 11
Kish 11
Lancaster 11
Manchester 11
Charlotte 10
Haiphong 10
Lappeenranta 10
Redwood City 10
Salamanca 10
Secaucus 10
Skopje 10
Baghdad 9
Bari 9
Columbus 9
Guangzhou 9
Mumbai 9
Turin 9
Amman 8
Bogotá 8
City of London 8
Totale 6.146
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 1.053
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 514
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 346
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 317
Longitudinal natural history of type I spinal muscular atrophy: A critical review 276
Assessing floppy infants: a new module 231
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 220
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 202
Developmental milestones in type I spinal muscular atrophy 196
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 184
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 178
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 175
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 172
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 169
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 169
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 164
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 164
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 163
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 161
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 156
Predominant distal muscle involvement in spinal muscular atrophy 156
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 151
Revised upper limb module for spinal muscular atrophy: Development of a new module 151
De novo partial 13q22-q34 trisomy with typical neurological and immunological findings: A case report with new genetic insights 151
Early treatment of type II SMA slows rate of progression of scoliosis 150
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 150
Longitudinal assessments in discordant twins with SMA 150
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 149
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 148
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 147
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 144
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 143
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 141
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 138
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 138
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 137
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 137
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 135
Nusinersen in type 0 spinal muscular atrophy: should we treat? 135
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 132
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 129
Revised upper limb module for spinal muscular atrophy: Development of a new module 125
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 124
Sleep disorders in spinal muscular atrophy 123
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 123
An observational study of functional abilities in infants, children, and adults with type 1 SMA 121
Developmental milestones in type I spinal muscular atrophy 121
Clinical Variability in Spinal Muscular Atrophy Type III. 121
Development of an academic disease registry for spinal muscular atrophy 120
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 119
Risdiplam in Type 1 Spinal Muscular Atrophy 110
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 109
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 108
Long term follow-up of scoliosis progression in type II SMA patients 107
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 107
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 104
An observational study of functional abilities in infants, children, and adults with type 1 SMA 104
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 104
Reply to: The need for evidence-based treatment decisions in spinal muscular atrophy type 0 104
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 101
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 92
Revised upper limb module for spinal muscular atrophy: 12 month changes 87
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 87
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 86
Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy 85
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 80
Point-of-care lung and diaphragm ultrasound in a patient with spinal muscular atrophy with respiratory distress type 1 77
An observational study of functional abilities in infants, children, and adults with type 1 SMA 75
Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients 75
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 64
Loss of ambulation in SMA III at the time of disease-modifying treatments: an international study 39
Development of the “SMA NNE,” a short neonatal neurological examination for newborns with spinal muscular atrophy 33
Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy 30
Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen 29
The phenotypic spectrum and genetic determinants of severe spinal muscular atrophy in individuals with a single SMN2 copy: an international retrospective observational study 26
Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry 23
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Totale 11.383
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.736
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022374 0 0 0 72 28 11 9 63 26 19 73 73
2022/20231.150 99 150 66 162 76 144 70 104 164 19 55 41
2023/2024992 34 165 34 88 51 172 152 54 19 49 80 94
2024/20251.684 41 24 108 82 134 92 71 67 249 139 374 303
2025/20265.498 524 135 305 591 872 1.339 724 197 229 267 198 117
2026/20271.175 211 402 350 212 0 0 0 0 0 0 0 0
Totale 11.383